<DOC>
	<DOC>NCT01300871</DOC>
	<brief_summary>This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).</brief_summary>
	<brief_title>Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alopecia</mesh_term>
	<criteria>Postmenopausal women Diagnosed with hormonereceptor positive breast cancer Commenced adjuvant endocrine therapy â‰¥ 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole Good command of the English language Under the care of a medical oncologist at Princess Margaret Hospital Previously received chemotherapy Recurrent and/or metastatic disease History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>